title: Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis.
abstract: A phospholipid-based nanoemulsion formulation of SQ641 (SQ641-NE) was active against intracellular Mycobacterium tuberculosis in J774A.1 mouse macrophages, although SQ641 by itself was not. Intravenous (i.v.) SQ641-NE was cleared from circulation and reached peak concentrations in lung and spleen in 1 h. In a murine tuberculosis (TB) model, 8 i.v. doses of SQ641-NE at 100 mg/kg of body weight over 4 weeks caused a 1.73 log10 CFU reduction of M. tuberculosis in spleen and were generally bacteriostatic in lungs.
authors.affiliation: Sequella, Inc., Rockville, Maryland, USA.
authors.forename: Boris
authors.initials: B
authors.lastname: Nikonenko
authors.forename: Venkata M
authors.initials: VM
authors.lastname: Reddy
authors.forename: Elena
authors.initials: E
authors.lastname: Bogatcheva
authors.forename: Marina
authors.initials: M
authors.lastname: Protopopova
authors.forename: Leo
authors.initials: L
authors.lastname: Einck
authors.forename: Carol A
authors.initials: CA
authors.lastname: Nacy
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002460:Cell Line; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity*; D014376:Tuberculosis / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents